Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164801 | 0.91 | GRM1 (0.59) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4167589 | 0.91 | GRM1 (0.61) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4175233 | 0.90 | GRM1 (0.59) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4169659 | 0.89 | GRM1 (0.58) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4165588 | 0.89 | GRM1 (0.62) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4170572 | 0.87 | GRM1 (0.61) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL13651682 | 0.87 | GRM1 (0.63) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4170560 | 0.85 | GRM1 (0.61) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4164601 | 0.84 | GRM1 (0.67) | GRM1MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4699767 | 0.83 | GRM1 (0.41) | GRM1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | claimed |
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | claimed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | claimed |
| EP-1999132-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM, LLC (BM) | 2008-12-10 | — | — | EP | claimed |
| WO-2007120454-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2007-10-25 | — | — | WO | claimed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| EP-1999132-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM, LLC (BM) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007120454-A1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | CNR1, CNR2, ITPR2 | GRM1 424/4885MAPT 2577/4885TP53 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.